TriangleDISEASE & TREATMENT SETTING
Cervical Cancer
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Cervical Cancer
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- unresolved
- derivation note
- Derived from NCI topic(s): Cervical Cancer; Cervical Cancer Treatment During Pregnancy. Strongest NCIt resolution: ambiguous. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
20 more-specific settings
Keytruda: metastatic cervical cancer with PD-L1 stated without a specific alteration after prior therapy →Tivdak: metastatic cervical cancer after prior therapy →KEYTRUDA: locally advanced cervical cancer →ALYMSYS: metastatic cervical cancer →KEYTRUDA: metastatic cervical cancer with PD-L1 stated without a specific alteration after prior therapy →Vegzelma: metastatic cervical cancer →KEYTRUDA QLEX: metastatic cervical cancer with PD-L1 stated without a specific alteration after prior therapy →KEYTRUDA QLEX: metastatic cervical cancer with PD-L1 stated without a specific alteration →Zirabev: metastatic cervical cancer →JOBEVNE: metastatic cervical cancer →MVASI: metastatic cervical cancer →HYCAMTIN: recurrent cervical cancer →KEYTRUDA: metastatic cervical cancer with PD-L1 stated without a specific alteration →KEYTRUDA QLEX: locally advanced cervical cancer →Avastin: metastatic cervical cancer →Stage IA Cervical Cancer →Stage IVB recurrent Cervical Cancer →Stage I Cervical Cancer →advanced Cervical Cancer →Stage II Cervical Cancer →
Study evidence for this setting
Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix
Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
Bupropion in Helping Adults Stop Smoking
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cance
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)
Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
Acceptability of Less Harmful Alternatives to Cigarettes
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
Indication-specific source history
2018-06-12 · Keytruda (pembrolizumab) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-cervical-cancer
- event id
- fda-b0651a0c19a6d573
- event date
- 2018-06-12
- event kind
- accelerated-approval
- drug or regimen
- Keytruda (pembrolizumab)
- source indication text
- Treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >/=1) as determined by an FDA approved test
- match phrase
- cervical cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-2a65b4873420497564e0
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2021-09-20 · Tivdak (tisotumab vedotin-tftv) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-cervical-cancer
- event id
- fda-6c67bc46de8bcf18
- event date
- 2021-09-20
- event kind
- accelerated-approval
- drug or regimen
- Tivdak (tisotumab vedotin-tftv)
- source indication text
- Treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy
- match phrase
- cervical cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-362e4da2080143274786
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2021-10-13 · Keytruda (pembrolizumab) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-cervical-cancer
- event id
- fda-330ea9c942f7cd84
- event date
- 2021-10-13
- event kind
- traditional-approval
- drug or regimen
- Keytruda (pembrolizumab)
- source indication text
- Treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >/=1) as determined by an FDA approved test
- match phrase
- cervical cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-2a65b4873420497564e0
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2024-04-29 · Tivdak (tisotumab vedotin-tftv) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-cervical-cancer
- event id
- fda-63e6ccc5f391819c
- event date
- 2024-04-29
- event kind
- traditional-approval
- drug or regimen
- Tivdak (tisotumab vedotin-tftv)
- source indication text
- Treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy
- match phrase
- cervical cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-362e4da2080143274786
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-cervical-cancer
- binding id
- ncit-C9039
- source collection
- ncit-concept
- source key
- C9039
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-cervical-cancer
- binding id
- ncit-C9311
- source collection
- ncit-concept
- source key
- C9311
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice